Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Toufigh Gordi"'
Autor:
Bret Berner, Toufigh Gordi
Publikováno v:
Drug Delivery Approaches
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose Etirinotecan pegol (EP), a long-acting topoisomerase-1 inhibitor, is a polyethylene glycol conjugate of irinotecan, with an intended indication for treatment of breast cancer with brain metastases. The objective of this study was to develop a
Explore this comprehensive discussion of the application of physiologically- and physicochemical-based models to guide drug delivery edited by leading experts in the field Drug Delivery Approaches: Perspectives from Pharmacokinetics and Pharmacodynam
Autor:
Daniel Dickerson, Lin Lu, Christie Fanton, Suresh Siddhanti, Brian Kotzin, Neha Dixit, Jonathan Zalevsky, Toufigh Gordi
Publikováno v:
Oral Presentations.
Background Impaired IL-2 production and dysfunction of regulatory T cells (Tregs) have been identified as key immunological defects leading to the breakdown of immune self-tolerance, a causative mechanism implicated in multiple autoimmune diseases. E
Publikováno v:
The Journal of Clinical Pharmacology. 56:723-732
Elvitegravir (EVG) is an HIV strand transfer integrase inhibitor approved for the treatment of HIV infection as a part of antiretroviral regimens containing cobicistat (COBI) or ritonavir (RTV) as a booster. The population pharmacokinetics of EVG in
Autor:
Rebecca Baillie, Priscilla Pegis, Herbert Vasquez, Gordon G. Power, Stephen R. Dueker, Le T. Vuong, Arlin B. Blood, Saira Abidi, Andrew O. Hopper, Toufigh Gordi
Publikováno v:
The Journal of Clinical Pharmacology. 54:1031-1037
Pharmacokinetic studies in the neonatal population are often limited by the small volume of blood that can be collected. The high sensitivity of (14) C-accelerator mass spectrometry (AMS) enables pharmacokinetic studies to be conducted with greatly r
Publikováno v:
Clinical Drug Investigation. 32:593-601
Approximately 75% of postmenopausal women experience vasomotor symptoms (hot flashes). Currently, hormone replacement therapy is the only approved treatment for hot flashes. However, its use has been associated with an increased risk of invasive brea
Autor:
Toufigh Gordi
Publikováno v:
Expert Review of Clinical Pharmacology. 5:157-162
In this article, drug discovery and preclinical development paradigms, as employed in today's pharmaceutical companies, are discussed. The antimalarial drug, artemisinin, is given as an example of a compound that is unlikely to be developed by a mode
Autor:
Michelle Heritier, Toufigh Gordi, Verne E. Cowles, Marilou Cramer, Eddie Hou, Sherwin L Schwartz
Publikováno v:
Expert Opinion on Drug Metabolism & Toxicology. 4:1235-1243
Glumetz (Depomed, Inc., Menlo Park, CA, USA) is a recently approved gastric retentive extended-release formulation of metformin (M-ER) that provides effective, sustained and well-tolerated glycemic control with once daily administration. Pharmacokine
Autor:
Toufigh Gordi, Hsiao D. Lieu, Richard A. Kerensky, Gregory O. von Mering, Ann Olmsted, John C. Shryock, Luiz Belardinelli, Brent Blackburn
Publikováno v:
Journal of Nuclear Cardiology. 14:514-520
Regadenoson is a selective A2A adenosine receptor agonist and vasodilator used to increase the heterogeneity of distribution of coronary blood flow during myocardial perfusion imaging. This study characterized the dose dependence of regadenoson-induc